Examining Key Updates in First-Line Treatment Options for Multiple Myeloma

home / peer-exchange / examining-key-updates-in-first-line-treatment-options-for-multiple-myeloma

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; Ryan Haumschild, PharmD, MBA, MS; Faith Davies, MD; Shachar Peles, MD, and Sagar Lonial MD, FACP discuss how quadruple therapy regimens incorporating CD38 antibodies have become the standard of care for both transplant-eligible and transplant-ineligible multiple myeloma patients, with treatment decisions guided by patient risk stratification, minimal residual disease monitoring, and the balance between achieving deep responses and maintaining quality of life.

Episodes

New content coming soon.
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo